Lipopeptide antibiotics | Health and Medicine

Full Article

Definition

Lipopeptide antibiotics are molecules synthesized primarily by soil bacteria through nonribosomal metabolic pathways. These molecules typically consist of a fatty acid connected to a short linear or cyclic amino acid chain, and they are generally acidic, making them highly soluble in water. In addition to naturally occurring lipopeptide antibiotics, synthetic and semisynthetic analogs have been developed. This class of antibiotics includes polymyxins, daptomycin, and echinocandins. Many require calcium for maximum antimicrobial activity; however, activity varies among lipopeptide antibiotics, with some active primarily against gram-positive bacteria and others, such as polymyxins, active against gram-negative bacteria.

Mechanism of Action

Many lipopeptide antibiotics bind to the cell membranes of specific microbial species and increase their permeability, although echinocandins primarily inhibit fungal cell wall synthesis. As the cell membrane becomes less stable, the cell contents leak out, and the bacterium or fungus dies.

Specific Compounds

The best-studied lipopeptide antibiotics are polymyxin B and polymyxin E (colistin), which were discovered in the 1940s. Isolated from the soil bacterium Bacillus polymyxa, polymyxins are used to treat a variety of gram-negative organisms, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, and Haemophilus influenzae. These compounds bind specifically to the lipopolysaccharide component of the outer membrane and disrupt the phospholipid bilayer. This detergent effect is effective against difficult-to-treat bacterial biofilms.

Commonly used commercial antibiotic ointments for wound healing combine polymyxin B with other antibiotics. An aerosolized form of polymyxin E is used to treat chronic P. aeruginosa infections in persons with cystic fibrosis. Polymyxin M (mattacin) is a polymyxin isolated from Paenibacillus kobensis. It is effective against both gram-positive and gram-negative bacteria.

Daptomycin, produced by Streptomyces roseosporus, is a lipopeptide antibiotic used for complicated skin and skin structure infections, bacteremia, and right-sided endocarditis. It binds to the bacterial cell membrane in a calcium-dependent manner, disrupting multiple aspects of cell membrane function. Daptomycin forms complexes with phosphatidylglycerol and cell wall precursors, interfering with cell wall synthesis. It also causes membrane depolarization and ion leakage, particularly potassium. These effects lead to the inhibition of various cellular processes, including protein, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) synthesis, ultimately resulting in rapid bacterial cell death. Daptomycin is effective against many clinically important gram-positive organisms, but it is too large to cross the outer membrane of gram-negative bacteria. Resistance to daptomycin is rare, although it can develop.

Echinocandins are large natural and semisynthetic compounds effective against Candida and Aspergillus species. They include caspofungin, micafungin, and anidulafungin, which are administered as intravenous injections. These antifungal compounds prevent the synthesis of (1,3)-beta-D-glucan, an essential component of the fungal cell wall. The semisynthetic antifungal compound anidulafungin, derived from a fermentation product of A. nidulans, also targets (1,3)-beta-D-glucan synthesis. A newer echinocandin, rezafungin, was approved by the US Food and Drug Administration in 2023 and has an extended half-life that allows once-weekly dosing for certain invasive Candida infections.

Impact

Lipopeptide antibiotics are fast-acting bactericidal and antifungal compounds, although resistance has been reported. The problem of antimicrobial resistance and the lack of new antibiotics has renewed interest in lipopeptide antibiotics, and they are often used for serious infections when other therapies fail. Daptomycin in particular is effective against methicillin-resistant and vancomycin-resistant Staphylococcus aureus. The main limitations of some of these compounds are poor solubility, tissue accumulation, and toxicity.

Bibliography

Cottagnoud, Philippe. “Daptomycin: A New Treatment for Insidious Infections Due to Gram-Positive Pathogens.” Swiss Medical Weekly, vol. 138, 2008, pp. 93–99.

Fischbach, Michael, et al. “Antibiotics for Emerging Pathogens.” Science, vol. 325, 2009, pp. 1089–93.

Patel, Shivali, and Stephen Saw. “Daptomycin - StatPearls.” NCBI, 17 Aug. 2024, www.ncbi.nlm.nih.gov/books/NBK470407. Accessed 22 June 2026.

Pirri, Giovanna, et al. “Lipopeptides as Anti-infectives: A Practical Perspective.” Central European Journal of Biology, vol. 4, 2009, pp. 258–73.

Raaijmakers, Jos M., et al. “Natural Functions of Lipopeptides from Bacillus and Pseudomonas: More than Surfactants and Antibiotics.” FEMS Microbiology Reviews, vol. 34, no. 6, 2010, pp. 1037–62, doi:10.1111/j.1574-6976.2010.00221.x. Accessed 22 June 2026.

Schuetz, Audrey N. “Rezafungin: A New Second-Generation Echinocandin.” CLSI AST News Update, vol. 10, no. 1, Apr. 2025, Clinical and Laboratory Standards Institute, clsi.org/resources/insights-blog/rezafungin-a-new-second-generation-echinocandin/. Accessed 22 June 2026.

Slingerland, Cornelis J., and Nathaniel I. Martin. “Recent Advances in the Development of Polymyxin Antibiotics: 2010–2023.” ACS Infectious Diseases, vol. 10, no. 4, Mar. 2024. ACS Publications, doi:10.1021/acsinfecdis.3c00630. Accessed 22 June 2026.

Syed, Yahiya Y. “Rezafungin: A Review in Invasive Candidiasis.” Drugs, vol. 84, 2024, Springer Nature, doi:10.1007/s40265-024-02134-0. Accessed 22 June 2026.

Wiman, Emanuel, et al. “Development of Novel Broad-spectrum Antimicrobial Lipopeptides Derived from Plantaricin NC8 β.” Scientific Reports, vol. 13, no. 1, 2023, pp. 1–16, doi:10.1038/s41598-023-31185-8. Accessed 22 June 2026.

Full Article

Definition

Lipopeptide antibiotics are molecules synthesized primarily by soil bacteria through nonribosomal metabolic pathways. These molecules typically consist of a fatty acid connected to a short linear or cyclic amino acid chain, and they are generally acidic, making them highly soluble in water. In addition to naturally occurring lipopeptide antibiotics, synthetic and semisynthetic analogs have been developed. This class of antibiotics includes polymyxins, daptomycin, and echinocandins. Many require calcium for maximum antimicrobial activity; however, activity varies among lipopeptide antibiotics, with some active primarily against gram-positive bacteria and others, such as polymyxins, active against gram-negative bacteria.

Mechanism of Action

Many lipopeptide antibiotics bind to the cell membranes of specific microbial species and increase their permeability, although echinocandins primarily inhibit fungal cell wall synthesis. As the cell membrane becomes less stable, the cell contents leak out, and the bacterium or fungus dies.

Specific Compounds

The best-studied lipopeptide antibiotics are polymyxin B and polymyxin E (colistin), which were discovered in the 1940s. Isolated from the soil bacterium Bacillus polymyxa, polymyxins are used to treat a variety of gram-negative organisms, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, and Haemophilus influenzae. These compounds bind specifically to the lipopolysaccharide component of the outer membrane and disrupt the phospholipid bilayer. This detergent effect is effective against difficult-to-treat bacterial biofilms.

Commonly used commercial antibiotic ointments for wound healing combine polymyxin B with other antibiotics. An aerosolized form of polymyxin E is used to treat chronic P. aeruginosa infections in persons with cystic fibrosis. Polymyxin M (mattacin) is a polymyxin isolated from Paenibacillus kobensis. It is effective against both gram-positive and gram-negative bacteria.

Daptomycin, produced by Streptomyces roseosporus, is a lipopeptide antibiotic used for complicated skin and skin structure infections, bacteremia, and right-sided endocarditis. It binds to the bacterial cell membrane in a calcium-dependent manner, disrupting multiple aspects of cell membrane function. Daptomycin forms complexes with phosphatidylglycerol and cell wall precursors, interfering with cell wall synthesis. It also causes membrane depolarization and ion leakage, particularly potassium. These effects lead to the inhibition of various cellular processes, including protein, deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) synthesis, ultimately resulting in rapid bacterial cell death. Daptomycin is effective against many clinically important gram-positive organisms, but it is too large to cross the outer membrane of gram-negative bacteria. Resistance to daptomycin is rare, although it can develop.

Echinocandins are large natural and semisynthetic compounds effective against Candida and Aspergillus species. They include caspofungin, micafungin, and anidulafungin, which are administered as intravenous injections. These antifungal compounds prevent the synthesis of (1,3)-beta-D-glucan, an essential component of the fungal cell wall. The semisynthetic antifungal compound anidulafungin, derived from a fermentation product of A. nidulans, also targets (1,3)-beta-D-glucan synthesis. A newer echinocandin, rezafungin, was approved by the US Food and Drug Administration in 2023 and has an extended half-life that allows once-weekly dosing for certain invasive Candida infections.

Impact

Lipopeptide antibiotics are fast-acting bactericidal and antifungal compounds, although resistance has been reported. The problem of antimicrobial resistance and the lack of new antibiotics has renewed interest in lipopeptide antibiotics, and they are often used for serious infections when other therapies fail. Daptomycin in particular is effective against methicillin-resistant and vancomycin-resistant Staphylococcus aureus. The main limitations of some of these compounds are poor solubility, tissue accumulation, and toxicity.

Bibliography

Cottagnoud, Philippe. “Daptomycin: A New Treatment for Insidious Infections Due to Gram-Positive Pathogens.” Swiss Medical Weekly, vol. 138, 2008, pp. 93–99.

Fischbach, Michael, et al. “Antibiotics for Emerging Pathogens.” Science, vol. 325, 2009, pp. 1089–93.

Patel, Shivali, and Stephen Saw. “Daptomycin - StatPearls.” NCBI, 17 Aug. 2024, www.ncbi.nlm.nih.gov/books/NBK470407. Accessed 22 June 2026.

Pirri, Giovanna, et al. “Lipopeptides as Anti-infectives: A Practical Perspective.” Central European Journal of Biology, vol. 4, 2009, pp. 258–73.

Raaijmakers, Jos M., et al. “Natural Functions of Lipopeptides from Bacillus and Pseudomonas: More than Surfactants and Antibiotics.” FEMS Microbiology Reviews, vol. 34, no. 6, 2010, pp. 1037–62, doi:10.1111/j.1574-6976.2010.00221.x. Accessed 22 June 2026.

Schuetz, Audrey N. “Rezafungin: A New Second-Generation Echinocandin.” CLSI AST News Update, vol. 10, no. 1, Apr. 2025, Clinical and Laboratory Standards Institute, clsi.org/resources/insights-blog/rezafungin-a-new-second-generation-echinocandin/. Accessed 22 June 2026.

Slingerland, Cornelis J., and Nathaniel I. Martin. “Recent Advances in the Development of Polymyxin Antibiotics: 2010–2023.” ACS Infectious Diseases, vol. 10, no. 4, Mar. 2024. ACS Publications, doi:10.1021/acsinfecdis.3c00630. Accessed 22 June 2026.

Syed, Yahiya Y. “Rezafungin: A Review in Invasive Candidiasis.” Drugs, vol. 84, 2024, Springer Nature, doi:10.1007/s40265-024-02134-0. Accessed 22 June 2026.

Wiman, Emanuel, et al. “Development of Novel Broad-spectrum Antimicrobial Lipopeptides Derived from Plantaricin NC8 β.” Scientific Reports, vol. 13, no. 1, 2023, pp. 1–16, doi:10.1038/s41598-023-31185-8. Accessed 22 June 2026.

More Like ThisRelated Articles

Related Articles (4)

Related Articles (4)

• Published In: Letters in Applied Microbiology, 2024, v. 77, n. 9. P. 1

  Authored By: da Costa, Rosiane Andrade; Andrade, Isadora Emanoela Pereira Costa; de Araújo, Thiago Fellipe; Fulgêncio, Débora Luiza Albano; Mendonça, Marise Leite; Rocha, Gabriel Iudy Yamaguchi; dos Santos, Raiana Moreira; Barreto, Cristine Chaves

  Publication Type: Academic Journal

• Published In: Journal of Applied Microbiology, 2023, v. 134, n. 4. P. 1

  Authored By: Lv, Ran; Li, Bin; Xiao, Ying; Zhang, Jingwen; Mai, Yuliang; Hu, Xiaoyong; Chen, Jiazhi

  Publication Type: Academic Journal

• Published In: Journal of Applied Microbiology, 2024, v. 135, n. 1. P. 1

  Authored By: El Arbi, Amel; Arnauld, Ségolène; Chataigné, Gabrielle; Lecouturier, Didier; Bricout, Alexandre; Gharsallah, Néji; Jacques, Philippe; Siah, Ali; Rochex, Alice

  Publication Type: Academic Journal

• Published In: Journal of Applied Microbiology, 2025, v. 136, n. 4. P. 1

  Authored By: Veiga, Fernanda C; de Felicio, Rafael; Trivella, Daniela B B; Macedo, Alexandre J

  Publication Type: Academic Journal